https://pubmed.ncbi.nlm.nih.gov/39309511/?dopt=Abstract
Schisanhenol ameliorates non-alcoholic fatty liver disease via inhibiting miR-802 activation of...
Non-alcoholic fatty liver disease (NAFLD), characterized by hepatic steatosis, is a common metabolic liver disease worldwide. Currently, satisfactory drugs for...
fatty liver disease